['diabetes', 'diabetes mellitus, type 2']
['semaglutide', 'dpp-4 inhibitor']

        Inclusion Criteria:

          -  Male or female, age at least 20 years at the time of signing informed consent

          -  HbA1c (glycosylated haemoglobin A1c) between 7.0% and 10.5% (53-91 mmol/mol) (both
             inclusive)

          -  Japanese subjects with type 2 diabetes mellitus (diagnosed clinically) and on stable
             treatment (defined as unchanged medication and unchanged dose) who are: a) on diet and
             exercise therapy for at least 30 days before Visit 1 (week -2). or b) on OAD
             monotherapy (either of SU (sulfonylurea), glinide, a-GI (a-glucosidase inhibitor) or
             TZD (thiazolidinediones)) within approved Japanese labelling in addition to diet and
             exercise therapy for at least 60 days before Visit 1 (week -2)

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using an adequate contraceptive method (e.g.,
             abstinence [not having sex], diaphragm, condom [by the partner], intrauterine device,
             sponge, spermicide or oral contraceptives) throughout the trial including the 5 week
             follow-up period

          -  Treatment with glucose lowering agent(s) other than stated in the inclusion criteria
             within 60 days before Visit 1 (week -2) and treatment with once weekly glucagon-like
             peptide-1 (GLP-1) receptor agonists within 90 days before Visit 1 (week -2). An
             exception is short-term treatment (below or equal to 7 days in total) with insulin in
             connection with inter-current illness

          -  Any disorder which, in the opinion of the investigator, might jeopardise subject's
             safety or compliance with the protocol

          -  History of chronic or idiopathic acute pancreatitis

          -  Screening calcitonin value above or equal to 50 ng/L (pg/mL)

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia syndrome type 2 (MEN2)

          -  Impaired renal function defined as estimated glomerular filtration rate (eGFR) below
             30 mL/min/1.73 m^2 per modification of diet in renal disease (MDRD) formula (4
             variable version)

          -  Acute coronary or cerebrovascular event within 90 days before randomisation (Visit 2
             [week 0])

          -  Heart failure, New York Heart Association (NYHA) class IV
      